Latest news with #LoteprednolEtabonateOphthalmicGel
Business Standard
11 hours ago
- Business
- Business Standard
Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic Gel
Lupin announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its abbreviated new drug application (ANDA) for Loteprednol Etabonate Ophthalmic Gel, 0.38%. The product is a generic equivalent of Lotemax SM Ophthalmic Gel, 0.38%, marketed by Bausch & Lomb Inc. Lupin is the exclusive first-to-file applicant for this product and is eligible for 180 days of generic drug exclusivity. The product will be manufactured at Lupins Pithampur facility in India. Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. According to IQVIA MAT data for May 2025, Loteprednol Etabonate Ophthalmic Gel, 0.38% (Reference Listed Drug: Lotemax SM) had estimated annual sales of $29 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.85% to Rs 1,978.05 on the BSE.
Business Upturn
17 hours ago
- Business
- Business Upturn
Top stocks in focus on July 2: LTI Mindtree, Hyundai Motor, MOIL, JSW Energy, RITES and more
Indian benchmark indices Sensex and Nifty ended higher in a range-bound session on Tuesday, July 1, supported by gains in heavyweights like Reliance Industries and HDFC Bank. On July 2, several stocks are likely to remain in focus due to recent corporate and regulatory updates. Stocks in Focus Karur Vysya Bank: Signed a bancassurance agreement with Kshema General Insurance for distributing non-life insurance products. LTI Mindtree: Launched 'GCC-as-a-Service' to support the expansion of global capability centres for enterprises. Lupin: Received US FDA approval for Loteprednol Etabonate Ophthalmic Gel, used post-eye surgery. Ather Energy: Introduced Rizta S with a 3.7kWh battery offering an IDC range of 159 km. Hyundai Motor: Reported total monthly sales of 60,924 units for June 2025, including 44,024 domestic and 16,900 export units. NIBE Ltd: Received an order worth ₹22.66 crore for turret structure assemblies from a major infra and defence company. Apeejay Surrendra Park Hotels: Signed hotel management agreements for THE Park Jaipur and Zone by The Park Govardhan. Moneyboxx Finance: Launched 'Salaried LAP' loan product for salaried customers. MOIL: Increased prices of all Ferro and Chemical grades by 2% over June 1 rates. NHPC: Rajendra Prasad Goyal appointed Chairman and MD for a two-month term. Keystone Realtors: To redevelop an 11.19-acre Mumbai project with expected revenue of over ₹4,500 crore. Swiggy: Rolled out a new meal section in its app featuring ₹99 single-meal options. JSW Energy: Green energy arm signed a battery storage project deal in Rajasthan. Ceigall India: Subsidiary secured an order worth ₹1,199 crore from NHAI. RITES: Secured a $3.6 million order from African Rail Company for overhauled locomotives. Hero MotoCorp: Reported a 10% increase in June sales and launched the VX2 e-scooter with battery-as-a-service. VMart: Posted a 12.6% YoY rise in operational revenue. India Pesticides: Expanded formulation plant capacity by 3,500 MTPA, reaching 10,000 MTPA. Cantabil Retail: Opened three new showrooms in June, raising its total to 607 outlets. SRM Contractors: CARE Ratings upgraded the company's long-term credit rating. Oil Marketing Companies: Awaiting finance ministry compensation for LPG-related losses, per petroleum minister's update. Bajaj Hindusthan Sugar: Received ₹631 crore from Lalitpur Power Generation Company via buyback. Zaggle: Entered a 5-year agreement with DTDC Express to provide Zaggle Zoyer and Save solutions. Ellenbarrie: Motilal Oswal Mutual Fund acquired 20.95 lakh shares at ₹511.1 each. Adani Enterprises: ADSTL completed acquisition of an 85.1% stake in Air Works. South Indian Bank: Q1 FY26 business update shows gross advances of ₹89,201 crore, marking 8.02% YoY growth. Havells India: CARE reaffirmed credit ratings for the company. Maruti Suzuki: Reported total June sales of 1.68 lakh units against a poll estimate of 1.70 lakh. JM Financial: Acquired 2.98% stake in JM Financial Credit Solutions for ₹88.97 crore. JHS Svendgaard: Re-appointed Nikhil Nanda as Managing Director for five years from July 2, 2025. Canara Bank: Shareholder Director Hemant Buch resigned effective July 1, 2025. Zen Technologies: Acquired a 76% stake in TISA Aerospace, now a subsidiary. Indian Energy Exchange: Appointed Dr. Puneet Chitkara as Head of Strategy effective July 1, 2025. SML Isuzu: Set July 9, 2025, as the record date for FY25 final dividend of ₹18/share. ITD Cementation India: Appointed Navneet Kabra as Senior VP – Operations. Lloyds Metals & Energy: DRI production for Q1FY26 stood at 79,033 tonnes, a 3% YoY increase. Ajooni Biotech: Re-appointed Jasjot Singh as MD for five years with revised remuneration. Godrej Properties: Sold a 2.5% stake in Vivrut Developers to a promoter group entity for ₹8.63 crore. Hyundai Motor: Posted a 6% YoY decline in June sales. Kajaria Ceramics: JP Morgan Funds sold 8.85 lakh shares at ₹1,067.88 each. Paras Defence: Promoter Sharad Virji Shah sold 1.56 lakh shares. Aarti Pharma: Orchid Family Trust offloaded 5.3 lakh shares. Fusion Microfinance: Promoter Devesh Sachdev sold 2.07 lakh shares. Asian Paints: Under investigation by the Competition Commission of India for alleged abuse of dominant position. Corporate Actions & Dividends NDR Auto Components: Ex-date for dividend of ₹2.75/share is July 3. VST Industries: Ex-date for dividend of ₹10/share is July 3. Bharat Seats: Ex-date for dividend of ₹1.1/share is July 2. Sika Interplant: Ex-date for dividend of ₹2.4/share is July 2. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash
The Hindu
a day ago
- Business
- The Hindu
Lupin gets U.S. FDA nod for Loteprednol Etabonate Ophthalmic Gel
Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for its abbreviated new drug application for Loteprednol Etabonate Ophthalmic Gel, 0.38% The approved product is bioequivalent to Lotemax SM Ophthalmic Gel of Bausch & Lomb Inc. Lupin is the exclusive first-to-file for the product and consequently eligible for 180 days of generic drug exclusivity. The product will be manufactured at its Pithampur facility, the company said. Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of $29 million in the U.S., it said citing IQVIA MAT May 2025 numbers. A corticosteroid, the drug is indicated for treatment of postoperative inflammation and pain following ocular surgery.
Business Standard
a day ago
- Business
- Business Standard
Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel
Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Gel, 0.38%. Loteprednol Etabonate Ophthalmic Gel, 0.38% is bioequivalent to Lotemax SM Ophthalmic Gel of Bausch & Lomb Inc. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Pithampur facility in India. Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of USD 29 million in the U.S. (IQVIA MAT May 2025).
Hans India
a day ago
- Business
- Hans India
Trade Setup for July 2: Doji candlestick pattern on the daily chart a sign of indecision.
After gaining nearly 700 points in the previous week, the Nifty entered consolidation mode, trading in a narrower range on Tuesday. Despite failing to breach Monday's high, the index managed to stay above the critical 25,500 mark for two straight sessions—a positive sign for bulls seeking stability. Tuesday's 90-point intraday range ended with the index posting modest gains. Unlike Monday's "higher-high" that ended lower, Tuesday formed a "lower-high" but still closed in the green, indicating underlying strength. Leading Tuesday's gain was Reliance Industries, now up in four of the last five sessions. It is only 5% away from its record high, following Nuvama's bullish target of ₹1,801. The Nifty Bank index also staged a strong recovery, closing 150 points higher, with PSU banks continuing their strong run—adding nearly ₹80,000 crore in market cap over six days. Market sentiment is now closely tied to two triggers: the much-anticipated India-US trade agreement, said to be in the final stages, and Q1 earnings updates, particularly from top banks and FMCG companies that can indicate the strength of domestic consumption. On the technical front, experts pointed to a Doji candlestick pattern on the daily chart—a sign of indecision. This could imply a turning point or ongoing consolidation. Immediate support levels are seen at 25,400–25,300, near the 78.6% Fibonacci retracement, while a dip below 25,350 may push the index toward 25,200. On the upside, the resistance zone lies between 25,670–25,740, with interim hurdles at 25,600–25,630. Stocks to Watch for July 2 Trading: Asian Paints: CCI orders probe into alleged abuse of dominant position after a complaint by Grasim. DGCCI to complete probe in 90 days. Hyundai Motor India: June sales at 60,924 units; SUVs form 67.6% of domestic sales. Maruti Suzuki: Sales at 1.68 lakh units, down 6.3% YoY; exports up 21.9%. Lupin: Gets USFDA approval for Loteprednol Etabonate Ophthalmic Gel for post-surgery inflammation. JSW Energy: Signs battery storage deal with Rajasthan Vidyut Utpadan Nigam for 250 MW / 500 MWh project. With geopolitical momentum and earnings season picking up, investors should brace for increased volatility and key breakouts.
